Advanced search
Publication Cover
Cancer Biology & Therapy Volume 15, 2014 - Issue 2
Submit an article Journal homepage
1,248
Views
8
CrossRef citations to date
0
Altmetric
Review

Beyond abiraterone

New hormonal therapies for metastatic castration-resistant prostate cancer

Álvaro Pinto Medical Oncology Department; University Hospital La Paz; IdiPAZ; Madrid, SpainCorrespondence[email protected]
Pages 149-155 | Received 28 Apr 2013, Accepted 06 Oct 2013, Published online: 01 Nov 2013

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Athanasios Dellis & Athanasios G. Papatsoris. (2016) Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer. Expert Opinion on Investigational Drugs 25:6, pages 697-707.
Read now

Articles from other publishers (7)

Nobuaki Matsubara, Hirofumi Mukai, Ako Hosono, Mai Onomura, Masaoki Sasaki, Yoko Yajima, Kensei Hashizume, Masanobu Yasuda, Miho Uemura & Christian Zurth. (2017) Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 80:6, pages 1073-1077.
Crossref
Nobuaki Matsubara, Hirofumi Mukai, Ako Hosono, Mai Onomura, Masaoki Sasaki, Yoko Yajima, Kensei Hashizume, Masanobu Yasuda, Miho Uemura & Christian Zurth. (2017) Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 80:6, pages 1063-1072.
Crossref
Giandomenico Roviello, Sandra Sigala, Shahneen Sandhu, Alberto Bonetta, Maria Rosa Cappelletti, Laura Zanotti, Alberto Bottini, Cora N. Sternberg, Stephen B. Fox & Daniele Generali. (2016) Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer 61, pages 111-121.
Crossref
Katherine Cotter, Badrinath Konety & Maria A. Ordonez. (2016) Contemporary Management of Prostate Cancer. F1000Research 5, pages 179.
Crossref
S Gunduz, H Bozcuk, M Yıldız, SS Goksu, M Uysal, D Arslan, AM Tatlı, H Mutlu, HS Coşkun & M Ozdogan. (2015) Line of abiraterone acetate in castration-resistant metastatic prostate cancer - Does it matter? report of a multi-institutional experience. Indian Journal of Cancer 52:4, pages 658.
Crossref
Jeremy S. Frieling, David Basanta & Conor C. Lynch. (2015) Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. Cancer Control 22:1, pages 109-120.
Crossref
Aslan Demir, Kursat Cecen, Mert Ali Karadag, Ramazan Kocaaslan & Levent Turkeri. (2014) The course of metastatic prostate cancer under treatment. SpringerPlus 3:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.